Jazz Pharmaceuticals Plc (NASDAQ: JAZZ)
Jazz Pharmaceuticals Plc Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Jazz Pharmaceuticals Plc Company Info
Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.
News & Analysis
Investing in Biotech Stocks in 2025
Investing in CBD Stocks
Here's what you need to know about the top CBD stocks.
Investing in Marijuana ETFs
Here's what you need to know about the top marijuana ETFs.
Best Medical Marijuana Stocks to Buy
Get in the know about medical marijuana stocks.
7 Steps to Investing in Marijuana Stocks
Here are seven steps to investing in the high-flying cannabis industry.
Prediction: These Could Be the Best-Performing Cannabis Stocks Through 2030
These two businesses may be sound, but generating returns in this industry has been tough, with no light at the end of the tunnel.
My Top Cannabis Stock to Buy in 2023 and Hold For 10 Years
The cannabis sector has been disappointing in recent years, but this company stands out.
2 Cannabis Stocks That Could Make You Richer
These two stocks could grow like weeds in the next five years and beyond.
Valuation
Earnings Transcripts
Jazz Pharmaceuticals PLC (JAZZ) Q3 2021 Earnings Call Transcript
JAZZ earnings call for the period ending September 30, 2021.
Jazz Pharmaceuticals PLC (JAZZ) Q2 2021 Earnings Call Transcript
JAZZ earnings call for the period ending June 30, 2021.
Jazz Pharmaceuticals PLC (JAZZ) Q1 2021 Earnings Call Transcript
JAZZ earnings call for the period ending March 31, 2021.
Jazz Pharmaceuticals PLC (JAZZ) Q4 2020 Earnings Call Transcript
JAZZ earnings call for the period ending December 31, 2020.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.